SwePub - search: WFRF:(Poole Wilson PA)

Enumeration	Reference	Cover	Find
1.	Kanai, M, et al. (author) 2023 swepub:Mat__t
2.	Phelan, CM, et al. (author) Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer 2017 In: Nature genetics. - : Springer Science and Business Media LLC. - 1546-1718 .- 1061-4036. ; 49:5, s. 680-691 Journal article (peer-reviewed)
3.	Sculpher, MJ, et al. (author) Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group 2000 In: European journal of heart failure. - 1388-9842. ; 2:4, s. 447-454 Journal article (peer-reviewed)
4.	Southey, MC, et al. (author) PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS 2016 In: Journal of medical genetics. - : BMJ. - 1468-6244 .- 0022-2593. ; 53:12, s. 800-811 Journal article (peer-reviewed)
5.	Bojesen, SE, et al. (author) Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer 2013 In: Nature genetics. - New york : Springer Science and Business Media LLC. - 1546-1718 .- 1061-4036. ; 45:4, s. 371-384 Journal article (peer-reviewed)
6.	Cleland, JGF, et al. (author) Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study 2001 In: European heart journal. - : Oxford University Press (OUP). - 0195-668X. ; 22:17, s. 1601-1612 Journal article (peer-reviewed)
7.	Cleland, JGF, et al. (author) Health economic benefits of treating patients with heart failure with high dose lisinopril versus low dose: The ATLAS study 1998 In: CIRCULATION. - 0009-7322. ; 98:17, s. 135-135 Conference paper (other academic/artistic)
8.	Ekman, Inger, 1952, et al. (author) Symptoms in patients with heart failure are prognostic predictors. Insights from COMET 2005 In: Journal of Cardiac Failure. - : Elsevier BV. - 1071-9164. ; 11:4, s. 288-92 Journal article (peer-reviewed)abstract BACKGROUND: Although functional status, as assessed by the New York Heart Association classification, is known to be a powerful prognostic marker in chronic heart failure (CHF), the significance of individual symptoms such as breathlessness and fatigue are unknown. OBJECTIVE: To assess the relative importance of self-reported severity of symptoms as predictors of outcomes in CHF. METHODS AND RESULTS: All 3029 patients randomized in the Carvedilol or Metoprolol European Trial (ie, COMET) study were included in the analysis. Mean follow-up was 58 months. Symptoms were assessed by 5-point scales. In a univariate analysis, worse scores for breathlessness, orthopnea and fatigue were all significantly related to increased mortality (all P < .0001) and development of worsening heart failure. In a multivariate Cox regression analysis including 16 baseline covariates, only the symptom of breathlessness remained significantly related to mortality (risk ratio [RR] 1.14 per unit: 95% CI 1.04-1.26; P = .01). Fatigue, but not breathlessness, remained a significant predictor for developing worsening heart failure (RR 1.09 per unit; 95% CI 1.02-1.18; P = .02). CONCLUSIONS: Fatigue and breathlessness, common symptoms in CHF, have important and independent long-term prognostic implications. Accordingly, symptoms need to be effectively evaluated not only because symptom alleviation is a target for treatment, but also because they guide prognosis in patients with CHF.
9.	Hampras, SS, et al. (author) Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer 2016 In: Oncotarget. - : Impact Journals, LLC. - 1949-2553. ; 7:43, s. 69097-69110 Journal article (peer-reviewed)
10.	Kuchenbaecker, KB, et al. (author) Identification of six new susceptibility loci for invasive epithelial ovarian cancer 2015 In: Nature genetics. - : Springer Science and Business Media LLC. - 1546-1718 .- 1061-4036. ; 47:2, s. 164-171 Journal article (peer-reviewed)
11.	Massie, BM, et al. (author) Excellent tolerability of high doses of lisinopril in the ATLAS trial 1998 In: CIRCULATION. - 0009-7322. ; 98:17, s. 82-82 Conference paper (other academic/artistic)
12.	Massie, BM, et al. (author) Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival 2001 In: Archives of internal medicine. - : American Medical Association (AMA). - 0003-9926. ; 161:2, s. 165-171 Journal article (peer-reviewed)
13.	Packer, M, et al. (author) Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group 1999 In: Circulation. - 0009-7322. ; 100:23, s. 2312-2318 Journal article (peer-reviewed)
14.	Permuth-Wey, J, et al. (author) Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31 2013 In: Nature communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 4, s. 1627- Journal article (peer-reviewed)
15.	Pharoah, PDP, et al. (author) GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer 2013 In: Nature genetics. - : Springer Science and Business Media LLC. - 1546-1718 .- 1061-4036. ; 45:4, s. 362-370 Journal article (peer-reviewed)
16.	Poole-Wilson, PA, et al. (author) Mode of death in heart failure: findings from the ATLAS trial 2003 In: Heart (British Cardiac Society). - : BMJ. - 1468-201X .- 0007-0769. ; 89:1, s. 42-48 Journal article (peer-reviewed)
17.	Ryden, L, et al. (author) Do all heart failure patients benefit from high dose lisinopril? Results from the ATLAS study 2000 In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. - 0735-1097. ; 35:2, s. 203A-203A Conference paper (other academic/artistic)
18.	Ryden, L, et al. (author) Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial 2000 In: European heart journal. - : Oxford University Press (OUP). - 0195-668X. ; 21:23, s. 1967-1978 Journal article (peer-reviewed)
19.	Shen, H, et al. (author) Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer 2013 In: Nature communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 4, s. 1628- Journal article (peer-reviewed)
20.	Uretsky, BF, et al. (author) Causes of sudden death in heart failure patients: Results from the ATLAS trial 1999 In: CIRCULATION. - 0009-7322. ; 100:18, s. 580-580 Conference paper (other academic/artistic)
21.	Uretsky, BF, et al. (author) Clinical-pathological correlation in the diagnosis of coronary disease as the cause of heart failure 1999 In: CIRCULATION. - 0009-7322. ; 100:18, s. 860-860 Conference paper (other academic/artistic)
22.	Uretsky, BF, et al. (author) Ischemia as a 'Trigger' for sudden death in patients with cardiomyopathy and heart failure secondary to coronary artery disease: Results from the ATLAS trial 1998 In: CIRCULATION. - 0009-7322. ; 98:17, s. 199-199 Conference paper (other academic/artistic)
23.	Uretsky, BF, et al. (author) The effect of performing an autopsy on classifying the cause of death in patients with heart failure 1999 In: CIRCULATION. - 0009-7322. ; 100:18, s. 861-861 Conference paper (other academic/artistic)

Skapa referenser, mejla, bekava och länka

Permalink

Träfflista för sökning "WFRF:(Poole Wilson PA) "

Refine your search

Year